| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1263 | |
| Phytochemical name or plant extracts | Urs-12-ene-3beta,6beta,16beta-triol-3-O-beta-galactopyranosyl-(1-->2)-beta-glucopyranoside | |
| PMID | 18039545 | |
| Literature evidence | Results showed that compound 2 decreased cell proliferation in a statistically significant manner at 25 microg/ml. | |
| IUPAC name | 3R,5S)-2-({[(2R,3S,5S)-2-{[(3S,5R,6aR,6bS,8S,8aS,11R,12S,14bR)-5,8-dihydroxy-4,4,6a,6b,8a,11,12,14b-octamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}methyl)-6-methyloxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponins | |
| Source of phytochemicals or plant Extracts | Silphium radula Nutt | |
| Geographical availability | Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas | |
| Plant parts | Leaves and stem | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | This result indicates Silphium as a potential source for anti-breast cancer compounds. Results showed that compound 2 decreased cell proliferation in a statistically significant manner at 25 µg/ml. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | NA | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:249173-1 | |
| Safety | NA |